TY - JOUR
T1 - Influence of bile on the absorption of halofantrine from lipid-based formulations
AU - Holm, Rene
AU - Tønsberg, Henrik
AU - Jørgensen, Erling B.
AU - Abedinpour, Puyan
AU - Farsad, Shafiq
AU - Müllertz, Anette
PY - 2012/6
Y1 - 2012/6
N2 - The bioavailability of the poorly soluble model drug halofantrine, dosed in a soy bean oil solution or in a self-nanoemulsifying drug delivery system (SNEDDS), at two levels of lipid, was assessed in rats. Three rat models were used: intact rats, sham-operated rats and bile duct cannulated rats. The study showed no difference in the pharmacokinetic parameters between intact and sham-operated rats. Tmax increased with lipid load for both oil solution and SNEDDS, whereas Cmax and the absolute bioavailability were significantly higher for the SNEDDS at both lipid dosing levels. Bile duct cannulation of the rats reduced the Cmax and the absolute bioavailability of halofantrine significantly, by a factor of 2, for all 4 treatments. These data clearly demonstrate that bile has an importance for the absorption of drugs from lipid-based formulations independent of the type.
AB - The bioavailability of the poorly soluble model drug halofantrine, dosed in a soy bean oil solution or in a self-nanoemulsifying drug delivery system (SNEDDS), at two levels of lipid, was assessed in rats. Three rat models were used: intact rats, sham-operated rats and bile duct cannulated rats. The study showed no difference in the pharmacokinetic parameters between intact and sham-operated rats. Tmax increased with lipid load for both oil solution and SNEDDS, whereas Cmax and the absolute bioavailability were significantly higher for the SNEDDS at both lipid dosing levels. Bile duct cannulation of the rats reduced the Cmax and the absolute bioavailability of halofantrine significantly, by a factor of 2, for all 4 treatments. These data clearly demonstrate that bile has an importance for the absorption of drugs from lipid-based formulations independent of the type.
U2 - 10.1016/j.ejpb.2012.03.005
DO - 10.1016/j.ejpb.2012.03.005
M3 - Journal article
C2 - 22465095
SN - 0939-6411
VL - 81
SP - 281
EP - 287
JO - European Journal of Pharmaceutics and Biopharmaceutics
JF - European Journal of Pharmaceutics and Biopharmaceutics
IS - 2
ER -